Saturday 7 November 2026 Export SLS’s income statement to Excel — free account

SELLAS Life Sciences Group, Inc.

SLS Healthcare Biotechnology

SELLAS Life Sciences Group, Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.0 million.

EPS: +28.6%
Free cash flow: −3.52%

Quarter to June 2026, against a year earlier

8.42 0.54 +6.85%

Follow SLS

Alert me

Market cap: $1.6B
P/E: 0.0×
Fwd P/E: −10.0×
Dividend yield: —
F-score: 2/9
Altman Z: −16.75
Beneish M: n/a
Dividend safety: n/a

Overview

	Older periods	Sep '25	Dec '25	Mar '26	Jun '26
ROE Full definition →	+8 more TTM periods Free account	(84.33%)	(66.88%)	(43.58%)	(39.63%)
ROA Full definition →		(66.47%)	(54.95%)	(39.50%)	(36.54%)
ROIC Full definition →		(1,391.37%)	0.00%	(9,146.22%)	0.00%
Return on Tangible Assets Full definition →		(60.15%)	(39.39%)	(28.13%)	(24.06%)
Average Days of Receivables Full definition →		—	—	—	—
Free Cash Flow per Share Full definition →		(0.28)	(0.26)	(0.16)	(0.15)
Free Cash Flow Full definition →		(30.62)	(28.39)	(28.16)	(28.42)
Other line items
Cash ROIC Full definition →		(34.00%)	(19.89%)	(13.12%)	(10.29%)
Accounts Payable Turnover Full definition →		0.00	0.00	0.00	0.00
Average Days of Payables Full definition →		0.00	0.00	0.00	0.00
Tax Rate Full definition →		0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →		0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →		1.18	1.06	0.96	0.88
Revenue per Share Full definition →		0.00	0.00	0.00	0.00
Operating CF per Share Full definition →		(0.28)	(0.26)	(0.16)	(0.15)
Capex per Share Full definition →		0.00	0.00	0.00	0.00

Show all line items

Columns are period end dates